MGFA has partnered with Bionews to feature the Myasthenia Gravis News feed on our website, providing the community with research updates, disease management insights, and relevant news. All content is original and produced by Bionews’ editorial staff, and perspectives from patients and caregivers. Information is not meant to replace or provide medical advice.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- Combining different treatment philosophies in my life with MG
by Sarah Bendiff on July 31, 2026 at 2:00 pmNavigating chronic illness often means balancing conventional medicine, complementary care, and well-meaning advice. One columnist reflects on finding a thoughtful, whole-person approach without losing sight of safety. The post Combining different treatment philosophies in my life with MG appeared first on Myasthenia Gravis News.
- Figuring out what helps me manage chronic pain, and what doesn’tby Sarah Bendiff on July 30, 2026 at 2:00 pm
Note: This column describes the author’s own experiences with various pain management techniques. Not everyone will have the same response to these modalities. Consult your doctor before starting or stopping a therapy. Living with a chronic illness means I am never truly well. Early in the morning, my muscles might already be sore. Late at The post Figuring out what helps me manage chronic pain, and what doesn’t appeared first on Myasthenia Gravis News.
- Add-on gMG treatment lowers costs, cuts time spent in hospital
by Steve Bryson, PhD on July 30, 2026 at 12:00 pmAdding Imaavy (nipocalimab-aahu) to standard treatment reduces hospital days by as much as 68% and lowers estimated annual hospital costs by $11,000 to $13,000 per patient for adults with generalized myasthenia gravis (gMG). That’s according to a post hoc analysis of data from the global Phase 3 Vivacity-MG3 clinical trial (NCT04951622), whose top-line, six-month results The post Add-on gMG treatment lowers costs, cuts time spent in hospital appeared first on Myasthenia Gravis News.
- Finding a solid rock to stand on in the relentless storm that is MG
by Mark Harrington on July 29, 2026 at 2:00 pmI have an unusual and slightly weird affection for old-time hymns. Something in me responds to the great hymns that have endured for thousands of years, such as “Sub Tuum Praesidium,” one of the oldest known hymns in Christianity. I feel a physical reaction to them. I also have an affinity for the old-time Gospel The post Finding a solid rock to stand on in the relentless storm that is MG appeared first on Myasthenia Gravis News.
- Trial tests combination therapy to boost gMG relief
by Michela Luciano, PhD on July 29, 2026 at 12:00 pmArgenx is advancing a clinical trial evaluating whether adding the experimental therapy empasiprubart to Vyvgart (efgartigimod alfa-fcab) can improve disease control in people with generalized myasthenia gravis (gMG) whose symptoms are only partly controlled with Vyvgart alone. The Phase 2a clinical trial, called ADAPT-Forward 1 (NCT07284420), is expected to enroll up to 70 adults, ages The post Trial tests combination therapy to boost gMG relief appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.